Nanocapsules: Preparation, characterization and therapeutic applications

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 255-276

  Gref, Ruxandra ^a   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

THERAPEUTIC APPLICATION;

EID: 84967360302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0012     Document Type: Chapter

References (86)

1. Fresta M, Cavallaro G, Giammona G, Wehrli E and Puglisi G (1996) Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 17:751.
2. Fattal E, Peracchia MT and Couvreur P (1997) Poly(alkylcyanoacrylate), in: Domb AJ, Kost J, Wiseman DM (eds.) Handbook of Biodegradable Polymers. Harwood Academic Publishers: Amsterdam.
3. Al Khouri N, Fessi H, Roblot-Treupel L, Devissaguet JP and Puisieux F (1986) An original procedure for preparing nanocapsules of polyalkyl-cyanoacrylates for interfacial polymerization. Pharm Acta Helv 61:274.
4. Al Khouri Fallouh N, Roblot-Treupel L, Fessi H, Devissaguet JP and Puisieux F (1986) Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 28:125.
5. Gallardo MM, Couarraze G, Denizot B, Treupel L, Couvreur P and Puisieux F (1993) Preparation and purification of isohexylcyanoacrylate nanocapsules. Int J Pharm 100:55.
6. Wohlgemuth M, Mächtle W and Mayer C (2000) Improved preparation and physical studies of polybutylcyanoacrylate nanocapsules. J Microencapsulation 17:437.
7. Chouinard F, Kan FW, Leroux JC, Foucher C and Lenaerts V (1991) Preparation and purification of polyisohexylcyanoacrylate nanocapsules. Int J Pharm 72:211.
8. Chouinard F, Buczkowski S and Lenaerts V (1994) Poly(alkylcyanoacrylate) nanocapsules: Physicochemical characterization and mechanism of formation. Pharm Res 11:869.
9. Puglisi G, Fresta M, Giammona G and Venture CA (1995) Influence of the preparation conditions in poly(ethylcyanoacrylate) nanocapsules formation. Int J Pharm 125:283.
10. El-Samaligy MS, Rojanasakul Y, Charlton JF, Weinstein GW and Lim JK (1996) Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit’s eye. Drug Del 3:93.
11. Ammoury N, Fessi H, Devissaguet JP, Puisieux F and Benita S (1989) Physicochemical characterization of polymeric nanocapsules and in vitro release evaluation of indomethacin as a drug model. STP Pharm 5:642.
12. Gürsoy A, Eroglu L, Ulutin S, Tasyürek M, Fessi H, Puisieux F and Devissaguet JP (1989) Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation. Int J Pharm 52:101.
13. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M and Maincent P (1992) Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: Polyisobutylcyanoacrylate, polylactic-co-glycolic acid, poly-epsilon-caprolactone. STP Pharm Sci 2:98.
14. Desai SD and Blanchard J (2000) Pluronic® F127-based ocular delivery systems containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Del J 7:201.
15. Aboubakar M, Puisieux F, Couvreur P, Deyme M and Vauthier C (1999) Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J Biomed Mater Res 47:568.
16. Damgé C, Michel C, Aprahamiam M and Couvreur P (1988) New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37:246.
17. Lowe PJ and Temple CS (1994) Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: Protection against proteases and effect in intestinal absorption in rats. J Pharm Pharmacol 46:547.
18. Damgé C, Vonderscher J, Marbach P and Pinget M (1997) Poly(alkylcyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol 49:949.
19. Damgé C, Vranckx H, Baldschmidt P and Couvreur P (1997) Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 86:1403.
20. Michel C, Aprahamiam M, Defontaine L, Couvreur P and Damgé C (1991) The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol 43:1.
21. Damgé C, Hillaire-Buys D, Puech R, Hoelizel A, Michel C and Ribes G (1995) Effects of orally administered insulin nanocapsules to normal and diabetic dogs. Diabetes Nutr Metab 8:3.
22. Roques M, Damgé C, Michel C, Staedel C, Cremel G and Hubert P (1992) Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes 41:451.
23. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A and Couvreur P (2000) Polyisobutylcyanoacrylate nanocapsules containing an acqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 17:707.
24. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C and Couvreur P (2000) EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. BBRC 279:401.
25. Chavany C, Le Doan T, Couvreur P, Puisieux F and Helene C (1992) Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 9:441.
26. Nakada Y, Fattal E, Foulquier M and Couvreur P (1996) Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 13:38.
27. Vrankx H, Demoustier M and Deleers M (1996) A new nanocapsule formulation with hydrophilic core: Application to the oral administration of salmon calcitonin in rats. Eur J Pharm Biopharm 42:345.
28. Watnasirichaikul S, Davies NM, Rades T and Tucker IG (2000) Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm Res 17:684-689.
29. Watnasirichaikul S, Rades T, Tucker IG and Davies NM (2002) Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int J Pharm 235:237-246.
30. Pitaksuteepong T, Davies NM, Tucker IG and Rades T (2002) Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerisation of water-in-oil microemulsions. Eur J Pharm Biopharm 53:335-342.
31. Grangier JL, Puygrenier M, Gauthier JC and Couvreur P (1991) Nanoparticles as carriers for growth hormone releasing factor (GRF). J Control Rel 15:3.
32. Fessi H, Devissaguet JP and Puisieux F (1986) Procédé de préparation des systèmes colloïdaux dispersibles d’une substance sous forme de nanocapsules. French Patent Application No. 8618444.
33. Fessi H, Puisieux F, Devissaguet JP, Ammoury N and Benita S (1989) Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm 55:R1-R4.
34. Mosqueira VCF, Legrand P, Pinto-Alphandary H, Puisieux F and Barratt G (2000) Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: Influence of the composition on physicochemical and structural properties. J Pharm Sci 89:614.
35. Bourdon O, Mosqueira V, Legrand P and Blais J (2000) A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorine encapsulated in surfacemodified submicronic oil/water carriers in HT29 tumor cells. J Photochem Photobiol B 55:164.
36. Mosqueira VCF, Legrand P, Gref R and Barratt G (1999) In vitro release kinetic studies of PEG-modified nanocapsules and nanospheres loaded with a lipophilic drug: Halofantrine base. Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials, 20-23 June, Boston, MA, 1074-1075.
37. Ameller T, Marsaud V, Legrand P, Gref R and Barratt G et Renoir JM (2003) Polyester - poly(ethylene glycol) nanospheres and nanocapsules loaded with the pure antioestrogen RU 58668: Physico-chemical and opsonisation properties. Pharm Res 20(7):1063-1070.
38. Ameller T, Marsaud V, Legrand P, Gref R and Barratt G et Renoir JM (2003) Polyester - poly(ethylene glycol) nanospheres and nanocapsules loaded with the pure antioestrogen RU 58668: Physico-chemical and opsonisation properties. Pharm Res 20(7):1063-1070.
39. Quintanar-Guerrero D, Allemann E, Doelker E and Fessi H (1998) Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res 15:1056.
40. Quintanar-Guerrero D, Fessi H, Doelker E and Allemann E (1997) Procédé de préparation de nanocapsules de type vésiculaire utilisable notamment comme vecteurs colloïdaux de principes actifs pharmaceutiques ou autres, French Patent 97.09.672.
41. Heurtault B, Saulnier P, Pech B, Proust JE and Benoit JP (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19:875-880.
42. Heurtault B, Saulnier P, Pech B, Proust JE and Benoit JP (2002) Properties of polyethyleneglycol 660 12 hydroxystearate at the triglyceride/water interface. Int J Pharm 242:176-170.
43. Heurtault B, Saulnier P, Pech B, Venier-Julienne MC, Proust JE, Phan-Tan-Luu R and Benoit JP (2003) The influence of lipid nanocapsule composition on their size distribution. Eur Pharm Sci 18:55-61.
44. Chupin V, de Kroon AI and de Kruijff B (2004) Molecular architecture of nanocapsules, bilayer-enclosed solid particles of Cisplatin. J Am Chem Soc 126:13816-13821.
45. Burger KN, Staffhorst RW, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM and de Kruijff B (2002) Nanocapsules: Lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 81-84.
46. Magalhaes NS, Fessi H, Puisieux F, Benita S and Seiller M (1995) An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. J Microencapsul 12:195.
47. Rollot JM, Couvreur P, Roblot-Treupel L and Puisieux F (1986) Physicochemical and morphological characterization of polyisobutyl cyanoacrylate nanocapsules. J Pharm Sci 75:361.
48. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H and Couvreur P (2003) Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Del Rev 55(4):519-548.
49. Calvo P, Remunan-Lopez C, Vila-Jato JL and Alonso MJ (1997) Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions. Coll Polym Sci 275:46.
50. Mosqueira VCF, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D and Barratt G (2001) Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967.
51. Mosqueira VCF, Legrand P, Gref R, Heurtault B, Appel M and Barratt G (1999) Interactions between a macrophage cell line (J774A1) and surface-modified poly(D,L-lactide) nanocapsules bearing poly(ethylene glycol). J Drug Targ 7:65.
52. Ammoury N, Fessi H, Devissaguet JP, Puisieux F and Benita S (1990) In vitro release kinetic pattern of indomethacin from poly(D,L-lactide) nanocapsules. J Pharm Sci 79:763.
53. Heurtault B, Legrand P, Mosqueira V, Devissaguet JP, Barratt G and Bories C (2001) In vitro antileishmanial properties of surface modified and primaquine loaded nanocapsules in Leishmania donovani intramacrophagic amastigotes. Ann Trop Med Parasitol 95:529.
54. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M and Benita S (1991) Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(D,L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res 8:101.
55. Marchais H, Benali S, Irache JM, Tharasse-Bloch C, Lafont O and Orecchioni AM (1998) Entrapment efficiency and initial release of phenylbutazone from nanocapsules prepared from different polyesters. Drug Dev Ind Pharm 24:883.
56. Kedzierewicz F, Thouvenot P, Monot I, Hoffman M and Maincent P (1998) Influence of different physicochemical conditions on the release of indium oxine from nanocapsules. J Biomed Mater Res 39:588.
57. Guterres SS, Fessi H, Barratt G, Puisieux F and Devissaguet JP (1995) Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: Gastrointestinal tolerance following intravenous and oral administration. Pharm Res 12:1545.
58. Andrieu V, Fessi H, Dubrasquet M, Devissaguet JP, Puisieux F and Benita S (1989) Pharmacokinetic evaluation of indomethacin nanocapsules. Drug Des Del 4:295.
59. Damgé C, Michel C, Aprahamiam M, Couvreur P and Devissaguet JP (1990) Nanocapsules as carriers for oral peptide delivery. J Control Rel 13:233.
60. Aboubakar M, Couvreur P, Pinto-Alphandary H, Gouritin B, Lacour B, Farinotti R, et al. (2000) Insulin-loaded nanocapsules for oral administration: In vitro and in vivo investigation. Drug Dev Res 49:109.
61. Aprahamiam M, Michel C, Humbert W, Devissaguet JP and Damgé C (1987) Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 61:69.
62. Sai P, Damgé C, Rivereau AS, Hoeltzel A and Gouin E (1996) Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. J Autoimmunity 9:713.
63. Dalenςon F, Amjaud Y, Lafforgue C, Derouin F and Fessi H (1998) Atovaquone and rifabutine-loaded nanocapsules: Formulation studies. Int J Pharm 153:127.
64. Calvo P, Remuñan C, Vila Jato JL and Alonso MJ (1997) Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron emulsions. Coll Polym Sci 275:46-53
65. Vila A, Sánchez A, Évora C, Soriano I, Vila Jato JL and Alonso MJ (2004) PEG-PLA nanoparticles as carriers for nasal protein/vaccine delivery. J Aerosol Med.
66. Prego C, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Torres D and Alonso MJ (2003) Chitosan and Chitosan-PEG nanocapsules: New carriers for improving the oral absorption of calcitonin.
67. Guterres SS, Fessi H, Barratt G, Puisieux F and Devissaguet JP (2000) Poly(D,L-lactide) nanocapsules containing diclofenac: Protection from muscular damage in rats. J Biomater Sci Polym Ed 11:1347.
68. Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet JP and Maincent P (1991) The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res 8:734.
69. Nishioka Y and Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Del Rev 47:55.
70. Marchal-Heussler L, Thouvenot P, Hoffman M and Maincent P (1999) Comparison of the biodistribution in mice of 111-indium oxine encapsulated into poly(lactic-co-glycolic)- D,L-85/15 and poly(epsilon-caprolactone) nanocapsules. J Pharm Sci 88:450.
71. Morin C, Barratt G, Fessi H, Devissaguet JP and Puisieux F (1994) Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. Int J Immunophar-macol 16:461.
72. Seyler I, Appel M, Devissaguet JP, Legrand P and Barratt G (1996) Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int J Immunopharmacol 18:385.
73. Seyler I, Appel M, Devissaguet JP, Legrand P and Barratt G (1999) Macrophage activation by a lipophilic derivative of muramyldipeptide within nanocapsules: Investigation of the mechanism of drug delivery. J Nanoparticle Res 1:91.
74. Barratt G, Puisieux F, Yu WP, Foucher C, Fessi H and Devissaguet JP (1994) Antimetastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int J Immunopharmacol 16:457.
75. Mosqueira VCF, Legrand P, Bories C, Devissaguet JP and Barratt G (2000) Comparative pharmacokinetics and in vivo efficacy of an intravenous formulation of halofantrine in long-circulating nanocapsules in Plasmodium berghei-infected mice. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, 7-13 July Paris, France; 490-491.
76. Langer K, Zimmer A and Kreuter J (1999) Acrylic nanoparticles for ocular drug delivery. STP Pharm Sci 7:445.
77. Legrand P, Barratt G, Mosqueira V, Fessi H and Devissaguet JP (1999) Polymeric nanocapsules as drug delivery systems, a review. STP Pharm Sci 9:411.
78. Marchal-Heussler L, Sirbat D, Hoffman M and Maincent P (1993) Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 10:386.
79. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL and Alonso MJ (1993) Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol. Pharm Res 10:80.
80. Calvo P, Thomas C, Alonso MJ, Vila Jato JL and Robinson JR (1994) Study of the mechanism of interaction of poly(e-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm 103:283.
81. Zimmer A, Kreuter J and Robinson JR (1991) Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsulation 8:497.
82. Calvo P, Vila-Jato JL and Alonso MJ (1997) Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: Stabilization approaches. Biomaterials 18:1305.
83. Calvo P, Vila-Jato JL and Alonso MJ (1997) Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 153:41.
84. De Campos A, Sanchez A and Alonso MJ (2001) Chitosan nanoparticles: A new vehicle for the improvement of the ocular retention of drugs. Application to cyclosporin A. Int J Pharm 224:159-168.
85. De Campos A, Sanchez A and Alonso MJ (2003) The effect of a PEG vs a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 20:73-81.
86. Calvo P, Vila-Jato JL and Alonso MJ (1997) Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 153:41-50.